OncoMatch/Clinical Trials/NCT06663306
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Is NCT06663306 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Pemetrexed and Bevacizumab for lung cancer (nsclc).
Treatment: Pemetrexed · Bevacizumab — This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: systemic anti-tumor treatment — for leptomeningeal metastasis
Unsatisfactory efficacy of LM,which defined as disease progression in LM,or LM-related neurological progression, while patients received standard systemic anti-tumor treatment
Cannot have received: pemetrexed intrathecal injection (pemetrexed)
History of pemetrexed and/or bevacizumab intrathecal Injection
Cannot have received: bevacizumab intrathecal injection (bevacizumab)
History of pemetrexed and/or bevacizumab intrathecal Injection
Cannot have received: brain/spinal cord radiation therapy
Brain/spinal cord radiation therapy within 1 week before enrollment
Lab requirements
Blood counts
Hemoglobin ≥ 90 g/L, neutrophil count ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L
Kidney function
Creatinine≤ 2.0 × ULN, or Creatinine clearance rate (CrCl) ≥ 50 mL/min
Liver function
Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); ALT and AST ≤ 2.5 × ULN
The laboratory test results meet the following criteria: Hemoglobin ≥ 90 g/L, neutrophil count ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L; Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN ; Creatinine≤ 2.0 × ULN,or Creatinine clearance rate (CrCl) ≥ 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify